pyrroles has been researched along with Carcinoma, Basal Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Compérat, EM; Hassler, MR; Rebhan, K; Shariat, SF; Wasinger, G | 1 |
| Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M | 1 |
2 review(s) available for pyrroles and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review.
Topics: Carcinoma, Basal Cell; Humans; Lymph Node Excision; Male; Middle Aged; Morpholines; Prostate; Prostatectomy; Prostatic Neoplasms; Pyrimidines; Pyrroles; Skin Neoplasms | 2022 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib | 2013 |